|
1
|
Oshimi K: Progress in understanding and
managing natural killer-cell malignancies. Br J Haematol.
139:532–544. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Suzuki R, Takeuchi K, Ohshima K and
Nakamura S: Extranodal NK/T-cell lymphoma: Diagnosis and treatment
cues. Hematol Oncol. 26:66–72. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M,
Sun L, Wei L, Li M, Liu C, et al: Distribution of lymphoid
neoplasms in China: Analysis of 4,638 cases according to the world
health organization classification. Am J Clin Pathol. 138:429–434.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim K, Kim WS, Jung CW, Im YH, Kang WK,
Lee MH, Park CH, Ko YH, Ree HJ and Park K: Clinical features of
peripheral T-cell lymphomas in 78 patients diagnosed according to
the revised European-American lymphoma (REAL) classification. Eur J
Cancer. 38:75–81. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee J, Park YH, Kim WS, Lee SS, Ryoo BY,
Yang SH, Park KW, Kang JH, Park JO, Lee SH, et al: Extranodal nasal
type NK/T-cell lymphoma: Elucidating clinical prognostic factors
for risk-based stratification of therapy. Eur J Cancer.
41:1402–1408. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chim CS, Ma SY, Au WY, Choy C, Lie AK,
Liang R, Yau CC and Kwong YL: Primary nasal natural killer cell
lymphoma: Long-term treatment outcome and relationship with the
international prognostic index. Blood. 103:216–221. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakamura S, Katoh E, Koshikawa T, Yatabe
Y, Nagasaka T, Ishida H, Tokoro Y, Koike K, Kagami Y, Ogura M, et
al: Clinicopathologic study of nasal T/NK-cell lymphoma among the
Japanese. Pathol Int. 47:38–53. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takahashi N, Miura I, Chubachi A, Miura AB
and Nakamura S: A clinicopathological study of 20 patients with
T/natural killer (NK)-cell lymphoma-associated hemophagocytic
syndrome with special reference to nasal and nasal-type NK/T-cell
lymphoma. Int J Hematol. 74:303–308. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY,
Chan CH, Cheung MM and Lau WH: Nonnasal lymphoma expressing the
natural killer cell marker CD56: A clinicopathologic study of 49
cases of an uncommon aggressive neoplasm. Blood. 89:4501–4513.
1997.PubMed/NCBI
|
|
10
|
Kluin PM, Feller A, Gaulard P, Jaffe ES,
Meijer CJ, Müller-Hermelink HK and Pileri S: PeripheralT/NK-cell
lymphoma: A report of the IXth Workshop of the European Association
for Haematopathology. Histopathology. 38:250–270. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Al-Hakeem DA, Fedele S, Carlos R and
Porter S: Extranodal NK/T-cell lymphoma, nasal type. Oral Oncol.
43:4–14. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Emile JF, Boulland ML, Haioun C, Kanavaros
P, Petrella T, Delfau-Larue MH, Bensussan A, Farcet JP and Gaulard
P: CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are
natural killer cell lymphomas. Blood. 87:1466–1473. 1996.PubMed/NCBI
|
|
13
|
Attygalle AD, Cabeçadas J, Gaulard P,
Jaffe ES, de Jong D, Ko YH, Said J and Klapper W: Peripheral T-cell
and NK-cell lymphomas and their mimics; taking a step
forward-report on the lymphoma workshop of the XVIth meeting of the
European Association for Haematopathology and the society for
Hematopathology. Histopathology. 64:171–199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO,
Park KR, Hong WP, Park IY, Hahn JS, Roh JK and Kim BS: Angiocentric
lymphoma of the head and neck: Patterns of systemic failure after
radiation treatment. J Clin Oncol. 18:54–63. 2000.PubMed/NCBI
|
|
15
|
Li YX, Yao B, Jin J, Wang WH, Liu YP, Song
YW, Wang SL, Liu XF, Zhou LQ, He XH, et al: Radiotherapy as primary
treatment for stage IE and IIE nasal natural killer/T-cell
lymphoma. J Clin Oncol. 24:181–189. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Koom WS, Chung EJ, Yang WI, Shim SJ, Suh
CO, Roh JK, Yoon JH and Kim GE: Angiocentric T-cell and NK/T-cell
lymphomas: Radiotherapeutic viewpoints. Int J Radiat Oncol Biol
Phys. 59:1127–1137. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Isobe K, Uno T, Tamaru J, Kawakami H, Ueno
N, Wakita H, Okada J, Itami J and Ito H: Extranodal natural
killer/T-cell lymphoma, nasal type: The significance of
radiotherapeutic parameters. Cancer. 106:609–615. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamaguchi M, Kita K, Miwa H, Nishii K, Oka
K, Ohno T, Shirakawa S and Fukumoto M: Frequent expression of
P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer.
76:2351–2356. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yong W, Zheng W, Zhu J, Zhang Y, Wang X,
Xie Y, Lin N, Xu B, Lu A and Li J: L-asparaginase in the treatment
of refractory and relapsed extranodal NK/T-cell lymphoma, nasal
type. Ann Hematol. 88:647–652. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jaccard A, Petit B, Girault S, Suarez F,
Gressin R, Zini JM, Coiteux V, Larroche C, Devidas A and
Thiéblemont C: L-asparaginase-based treatment of 15 western
patients with extranodal NK/T-cell lymphoma and leukemia and a
review of the literature. Ann Oncol. 20:110–116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nagafuji K, Fujisaki T, Arima F and
Ohshima K: L-asparaginase induced durable remission of relapsed
nasal NK/T-cell lymphoma after autologous peripheral blood stem
cell transplantation. Int J Hematol. 74:447–450. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Obama K, Tara M and Niina K:
L-asparaginase-Based induction therapy for advanced extranodal
NK/T-cell lymphoma. Int J Hematol. 78:248–250. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin N, Song Y, Zheng W, Tu M, Xie Y, Wang
X, Ping L, Ying Z, Zhang C, Deng L, et al: A prospective phase II
study of L-asparaginase- CHOP plus radiation in newly diagnosed
extranodal NK/T-cell lymphoma, nasal type. J Hematol Oncol.
6:442013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
The International Non-Hodgkin's Lymphoma
Prognostic Factors Project: A predictive model for aggressive
non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma
Prognostic Factors Project. N Engl J Med. 329:987–994.
1993.PubMed/NCBI
|
|
25
|
Miller AB, Hoogstraten B, Staquet M and
Winkler A: Reporting results of cancer treatment. Cancer.
47:207–214. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee J, Kim WS, Park YH, Park SH, Park KW,
Kang JH, Lee SS, Lee SI, Lee SH, Kim K, et al: Nasal-type NK/T cell
lymphoma: Clinical features and treatment outcome. Br J Cancer.
92:1226–1230. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim BS, Kim TY, Kim CW, Kim JY, Heo DS,
Bang YJ and Kim NK: Therapeutic outcome of extranodal NK/T-cell
lymphoma initially treated with chemotherapy-result of chemotherapy
in NK/T-cell lymphoma. Acta Oncol. 42:779–783. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cheung MM, Chan JK, Lau WH, Ngan RK and
Foo WW: Early stage nasal NK/T-cell lymphoma: Clinical outcome,
prognostic factors, and the effect of treatment modality. Int J
Radiat Oncol Biol Phys. 54:182–190. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim WS, Song SY, Ahn YC, Ko YH, Baek CH,
Kim DY, Yoon SS, Lee HG, Kang WK, Lee HJ, et al: CHOP followed by
involved field radiation: Is it optimal for localized nasal natural
killer/T-cell lymphoma? Ann Oncol. 12:349–352. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim SJ and Kim WS: Treatment of localized
extranodal NK/T cell lymphoma, nasal type. Int J Hematol.
92:690–696. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang ZY, Li YX, Wang WH, Jin J, Wang H,
Song YW, Liu QF, Wang SL, Liu YP, Qi SN, et al: Primary
radiotherapy showed favorable outcome in treating extranodal
nasal-type NK/T-cell lymphoma in children and adolescents. Blood.
114:4771–4776. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li CC, Tien HF, Tang JL, Yao M, Chen YC,
Su IJ, Hsu SM and Hong RL: Treatment outcome and pattern of failure
in 77 patients with sinonasal natural killer/T-cell or T-cell
lymphoma. Cancer. 100:366–375. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang B, Li XQ, Ma X, Hong X, Lu H and Guo
Y: Immunohistochemical expression and clinical significance of
P-glycoprotein in previously untreated extranodal NK/T-cell
lymphoma, nasal type. Am J Hematol. 83:795–799. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chaudhary PM, Mechetner EB and Roninson
IB: Expression and activity of the multidrug resistance
P-glycoprotein in human peripheral blood lymphocytes. Blood.
80:2735–2739. 1992.PubMed/NCBI
|
|
35
|
Charamella LJ, Meyer C, Thompson GE and
Dimitrov NV: Chemotherapeutic agents and modulation of natural
killer cell activity in vitro. J Immunopharmacol. 7:53–65. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ando M, Sugimoto K, Kitoh T, Sasaki M,
Mukai K, Ando J, Egashira M, Schuster SM and Oshimi K: Selective
apoptosis of natural killer-cell tumours by l-asparaginase. Br J
Haematol. 130:860–868. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yong W, Zhang Y and Zheng W: The efficacy
of L-asparaginase in the treatment of refractory midline peripheral
T-cell lymphoma. Zhong Hua Xue Ye Xue Za Zhi. 21:577–579. 2000.(In
Chinese).
|
|
38
|
Silverman LB, Supko JG, Stevenson KE,
Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell
L, Cole PD, et al: Intravenous PEG-asparaginase during remission
induction in children and adolescents with newly diagnosed acute
lymphoblastic leukemia. Blood. 115:1351–1353. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Avramis VI, Sencer S, Periclou AP, Sather
H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J,
Gaynon PS, et al: A randomized comparison of native Escherichia
coli asparaginase and polyethylene glycol conjugated asparaginase
for treatment of children with newly diagnosed standard-risk acute
lymphoblastic leukemia: A Children's cancer group study. Blood.
99:1986–1994. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cooperation Group of Phase II Clinical
Trial of PEG-Asp: Comparison of polyethylene glycol conjugated
asparaginase and L-asparaginase for treatment of childhood acute
lymphoblastic leukemia. Zhong Hua Xue Ye Xue Za Zhi. 29:29–33.
2008.(In Chinese.).
|
|
41
|
Kim YR, Kim JS, Kim SJ, Jung HA, Kim SJ,
Kim WS, Lee HW, Eom HS, Jeong SH, Park JS, et al: Lymphopenia is an
important prognostic factor in peripheral T-cell lymphoma (NOS)
treated with anthracycline-containing chemotherapy. J Hematol
Oncol. 4:342011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chauchet A, Michallet AS, Berger F,
Bedgedjian I, Deconinck E, Sebban C, Antal D, Orfeuvre H, Corront
B, Petrella T, et al: Complete remission after first-line
radio-chemotherapy as predictor of survival in extranodal NK/T cell
lymphoma. J Hematol Oncol. 5:272012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kim SJ, Kim BS, Choi CW, Choi J, Kim I,
Lee YH and Kim JS: Ki-67 expression is predictive of prognosis in
patients with stage I/II extranodal NK/T-cell lymphoma, nasal type.
Ann Oncol. 18:1382–1387. 2007. View Article : Google Scholar : PubMed/NCBI
|
